Skip to content
Screener

Travere Therapeutics, Inc. TVTX Q1 2026 earnings

Reported May 4, 2026 · After market close

Revenue$127.2MMiss by $9.0M
EPS-$0.39Miss by $0.09
Revenue estimate$136.2M
EPS estimate-$0.30

Next report

Oct 29, 2026 (in a month)
Revenue estimate$195.7M
EPS estimate$0.05

Financials

Q1 2026

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.74B+72.3%
Enterprise value$2.68B+65.5%
P/S5.1×-0.7×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp

Returns & leverage

See full
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Segments

By segment

See full
Reportable Segment$127.2M+55.6%

By product

See full
License and collaboration revenue$2.7M-54.1%

FAQ

When did Travere Therapeutics, Inc. report Q1 2026 earnings?
Travere Therapeutics, Inc. (TVTX) reported Q1 2026 earnings on May 4, 2026 after market close.
What were Travere Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Travere Therapeutics, Inc. reported revenue of $127.2M and eps of $-0.39 for Q1 2026.
Did Travere Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $136.2M by $9.0M. EPS missed the consensus estimate of $-0.30 by $0.09.
How did Travere Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.6% from $81.7M a year earlier and eps grew 17.0% from $-0.47.
Where can I find Travere Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001438533-26-000041) and the 10-Q periodic report (0001438533-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.